Insightec Gets FDA Blessing for Study of Exablate Neuro to Treat Parkinsonís Involuntary Movements

Share

(November 2, 2017) - The U.S. Food and Drug Administration has granted approval to Insightec to start a pivotal study of its Exablate Neuro technology. The ultrasound therapy aims to treat advanced Parkinson’s disease patients with involuntary muscle movements and motor fluctuations who don’t respond to medication. Read more

Click for a printer friendly version

Back to top